MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2026033876

Медицинская библиотека · Blood · 2026

Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.

Velazquez Giuliano Filippini, Schmid Christoph, Gras Luuk, Baaij Laurien Greetje Antoinette, Koster Linda, Kröger Nicolaus, Weller Jan Frederic, Schroeder Thomas, Sockel Katja, Bethge Wolfgang Andreas, Sala Elisa, Morsink Linde M, Maertens Johan A, Passweg Jakob R, Platzbecker Uwe, Potter Victoria, Vydra Jan, Spyridonidis Alexandros, Onida Francesco, Scheid Christof, Gurnari Carmelo, Drozd-Sokolowska Joanna Ewa, Raj Kavita, Robin Marie, McLornan Donal P

СтатьяПеревод пока не подготовлен

Аннотация

Myelodysplastic neoplasms (MDS) relapsing after allogeneic stem cell transplantation (alloSCT) have a poor prognosis. A second alloSCT (alloSCT2) can offer durable remission, however, earlier studies reported <20% long-term survival. Here we summarize contemporary outcome and risk factors after alloSCT2 (2012-2023), particularly focusing on donor change (DoC). We included 313 adults undergoing alloSCT2 for MDS relapse. Donors for alloSCT2 were matched- related/unrelated/haploidentical in 19%/62%/19%, with DoC reported in 71%. Two-year overall-/progression-free survival (OS/PFS), cumulative relapse incidence (RI) and non-relapse mortality (NRM) from alloSCT2 were 45%/33%/37%/30%. Outcome improved over time (2y-OS/PFS: 51%/39% in years 2018-2023). In multivariable analyses, DoC was associated with lower risk of relapse (HR=0.56, 95%-CI: 0.36-0.89), a finding never observed after alloSCT2 for acute leukemia. Additionally, adverse cytogenetics were correlated with relapse risk (HR=1.93, 95%-CI: 1.18-3.17). Risk of NRM decreased in more recent years (HR=0.88, per year later) and in patients with Karnofsky performance score (KPS) ≥90 at alloSCT2 (HR=0.59). Concerning survival, remission after alloSCT1 ≥12 months (HR=0.62/0.67) and KPS ≥90 (HR=0.68/0.69) were associated with better OS/PFS. In summary, we report improved outcomes of alloSCT2 in MDS in more recent years and demonstrate superior disease control by DoC, although a trend toward increased NRM precluded a significant survival benefit.

Для цитирования: Velazquez Giuliano Filippini, Schmid Christoph, Gras Luuk, Baaij Laurien Greetje Antoinette, Koster Linda, Kröger Nicolaus, Weller Jan Frederic, Schroeder Thomas, Sockel Katja, Bethge Wolfgang Andreas, Sala Elisa, Morsink Linde M, Maertens Johan A, Passweg Jakob R, Platzbecker Uwe, Potter Victoria, Vydra Jan, Spyridonidis Alexandros, Onida Francesco, Scheid Christof, Gurnari Carmelo, Drozd-Sokolowska Joanna Ewa, Raj Kavita, Robin Marie, McLornan Donal P. Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.. Blood. 2026. DOI: 10.1182/blood.2026033876.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.